NAYA Biosciences Unveils AI-Optimized Antibody for Cancer Treatment

NAYA Biosciences Introduces AI-Optimized Cancer Treatment

NAYA Biosciences (NASDAQ: NAYA), a life science portfolio company, has announced the development of NY-500, a novel AI-optimized PD-1 x VEGF bifunctional antibody designed to treat hepatocellular carcinoma (HCC) and other solid tumors 1

1

. This innovative approach combines the company's proprietary FLEX antibody platform with artificial intelligence optimization through a partnership with MabSilico, an AI and deep technology-focused company 1

1

.

Leveraging AI for Enhanced Drug Development

The use of AI in optimizing NY-500's design represents a significant step forward in drug development. By partnering with MabSilico, NAYA Biosciences aims to accelerate the creation of best-in-class candidates for validated therapeutic targets 1

1

. This collaboration highlights the growing trend of integrating AI technologies into pharmaceutical research and development processes.

Potential to Surpass Current Immunotherapy Standards

Recent clinical data with ivonescimab, another PD-1 x VEGF antibody, has shown superiority in non-small-cell lung cancer (NSCLC) compared to Keytruda®, the leading first-line immunotherapy standard-of-care in multiple solid tumors 1

1

. This breakthrough paves the way for a new generation of PD-(L)1 therapeutic candidates, with NY-500 positioned to potentially offer improved outcomes for cancer patients.

Mechanism of Action and Market Potential

NY-500 targets both PD-1, a key immune checkpoint, and VEGF, a vascular endothelial growth factor 1

1

. This dual-targeting approach aims to improve T-cell infiltration into tumors and enhance immune response while disrupting tumor vasculature 1

1

. The PD(L)1 market is expected to exceed $50 billion in 2025, according to IQVIA, highlighting the significant commercial potential for successful therapies in this space 1

1

2

2

.

Clinical Trial Timeline and Expanding Pipeline

NAYA Biosciences plans to initiate monotherapy phase 1/2a clinical trials for NY-500 in early 2026 1

1

. The company is also developing other promising candidates, including NY-303, a GPC3-targeting bifunctional antibody currently in phase 1/2 clinical trials for HCC patients not responding to existing PD-1 +/- VEGF therapies 1

1

2

2

.

Company Background and Recent Developments

NAYA Biosciences, with a market cap of $3.9 million, employs a hub & spoke model to efficiently acquire, develop, and partner assets 2

2

. The company recently completed a merger with INVO Bioscience, combining INVO's fertility business with NAYA's clinical-stage assets 2

2

. This strategic move aims to leverage combined resources for enhanced growth and innovation in oncology, autoimmune diseases, and women's health 2

2

.

Financial Health and Stock Performance

Despite its relatively small market cap, NAYA Biosciences has shown strong recent performance, with a 10.85% gain in stock price over the past week 2

2

. The company boasts an impressive InvestingPro Financial Health Score of 3.24, rated as GREAT, suggesting a solid foundation for executing its development strategy 2

2

.